**Background of GNMT Antibodies**
Glycine N-methyltransferase (GNMT) is a metabolic enzyme primarily expressed in the liver, playing a critical role in regulating methionine and folate metabolism. It catalyzes the methylation of glycine using *S*-adenosylmethionine (SAMe), influencing cellular methylation potential and maintaining homeostasis of one-carbon units. Dysregulation of GNMT has been linked to liver diseases, metabolic disorders, and cancers, particularly hepatocellular carcinoma (HCC).
GNMT antibodies are essential tools for studying this enzyme’s expression, localization, and function in both normal and pathological contexts. These antibodies enable detection of GNMT protein levels via techniques like Western blotting, immunohistochemistry, and immunofluorescence. Researchers use them to explore GNMT’s role in detoxification, its tumor-suppressive properties, and its interaction with pathways involved in oxidative stress and apoptosis.
The development of specific and high-affinity GNMT antibodies has advanced diagnostic and therapeutic research. For instance, reduced GNMT expression is a biomarker for HCC progression, making these antibodies valuable in cancer studies. Additionally, they aid in understanding metabolic syndromes, such as hyperhomocysteinemia and diabetes, where GNMT activity is often altered. Ongoing research continues to highlight GNMT’s multifaceted roles, underpinning the importance of reliable antibodies for mechanistic and clinical investigations.